Construction of retroviral vectors with enhanced efficiency of transgene expression

Journal of Virological Methods

Volumn 121, Issue 2, 2004, Pages 127-136

  Hahm, Sung Ho ^a   Yi, Youngsuk ^b   Lee, Dug Keun ^b   Noh, Moon Jong ^c   Yun, Lillian ^b   Hwang, Sally ^b   Lee, Kwan Hee ^b,d  

^a Omegagen   (United States)

^b GeneDx Inc   (United States)

^c Kolon Industries Inc   (South Korea)

^d Inha University School of Medicine   (South Korea)

Author keywords

Enhancer; Gene delivery; Gene expression; Gene therapy; Promoter; Retrovirus; Transcription; Vectors; VSV G

Indexed keywords

GAG PROTEIN; POL PROTEIN; RETROVIRUS VECTOR; VIRUS ENVELOPE PROTEIN;

5' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; CYTOMEGALOVIRUS; EXON; GENE CONSTRUCT; GENE EXPRESSION; GENE LOCATION; GENE SEQUENCE; GENETIC CODE; GENOME; HOMOLOGOUS RECOMBINATION; HOST; HYBRID; IMMEDIATE EARLY GENE; INTRON; MOLONEY LEUKEMIA ONCOVIRUS; MOLONEY MURINE SARCOMA ONCOVIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; VIRUS RECOMBINANT; VIRUS TITRATION;

ANIMALS; CYTOMEGALOVIRUS; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; IMMEDIATE-EARLY PROTEINS; MICE; MOLONEY MURINE LEUKEMIA VIRUS; MOLONEY MURINE SARCOMA VIRUS; NIH 3T3 CELLS; PEPTIDE ELONGATION FACTOR 1; PROMOTER REGIONS (GENETICS); TRANSGENES; VIRUS REPLICATION;

CUCUMBER MOSAIC VIRUS; MOLONEY MURINE LEUKEMIA VIRUS; MOLONEY MURINE SARCOMA VIRUS; MURINAE; MURINE LEUKEMIA VIRUS; MURINE SARCOMA VIRUS; PAN TROGLODYTES; UNIDENTIFIED RETROVIRUS;

EID: 4644347757     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2004.05.014     Document Type: Article

References (39)

1. Armentano D., Yu S.F., Kantoff P.W., von Ruden T., Anderson W.F., Gilboa E. Effect of internal viral sequences on the utility of retroviral vectors. J. Virol. 61:1987;1647-1650
2. Baum C., Dullmann J., Li Z., Fehse B., Meyer J., Williams D.A., von Kalle C. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood. 101:2003;2099-2114
3. Bender M.A., Palmer T.D., Gelinas R.E., Miller A.D. Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region. J. Virol. 61:1987;1639-1646
4. Burgess-Beusse B., Farrell C., Gaszner M., Litt M., Mutskov V., Recillas-Targa F., Simpson M., West A., Felsenfeld G. The insulation of genes from external enhancers and silencing chromatin. Proc. Natl. Acad. Sci. U.S.A. 99(Suppl 4):2002;16433-16437
5. Burns J.C., Friedmann T., Driever W., Burrascano M., Yee J.K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U.S.A. 90:1993;8033-8037
6. Bushman F. Targeting retroviral integration? Mol. Ther. 6:2002;570-571
7. Chen J., Reeves L., Sanburn N., Croop J., Williams D.A., Cornetta K. Packaging cell line DNA contamination of vector supernatants: implication for laboratory and clinical research. Virology. 282:2001;186-197
8. Danos O., Mulligan R.C. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. U.S.A. 85:1988;6460-6464
9. Edwards S.A., Fan H. gag-Related polyproteins of Moloney murine leukemia virus: evidence for independent synthesis of glycosylated and unglycosylated forms. J. Virol. 30:1979;551-563
10. Emery D.W., Yannaki E., Tubb J., Stamatoyannopoulos G. A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc. Natl. Acad. Sci. U.S.A. 97:2000;9150-9155
11. Gorman C.M., Gies D., McCray G., Huang M. The human cytomegalovirus major immediate early promoter can be trans-activated by adenovirus early proteins. Virology. 171:1989;377-385
12. Goulaouic H., Chow S.A. Directed integration of viral DNA mediated by fusion proteins consisting of human immunodeficiency virus type 1 integrase and Escherichia coli LexA protein. J. Virol. 70:1996;37-46
13. Hacein-Bey-Abina S., von Kalle C., Schmidt M., Le Deist F., Wulffraat N., McIntyre E., Radford I., Villeval J.L., Fraser C.C., Cavazzana-Calvo M., Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348:2003;255-256
14. Hansen A.C., Pedersen F.S. Safety features of retroviral vectors. Curr. Opin. Mol. Ther. 4:2002;324-333
15. Hawley R.G. Progress toward vector design for hematopoietic stem cell gene therapy. Curr. Gene Ther. 1:2001;1-17
16. Kaiser J. Gene therapy. Seeking the cause of induced leukemias in X-SCID trial. Science. 299:2003;495
17. Kappes J.C., Wu X. Safety considerations in vector development. Somat. Cell Mol. Genet. 26:2001;147-158
18. Katz R.A., Merkel G., Skalka A.M. Targeting of retroviral integrase by fusion to a heterologous DNA binding domain: in vitro activities and incorporation of a fusion protein into viral particles. Virology. 217:1996;178-190
19. Kim S.H., Yu S.S., Park J.S., Robbins P.D., An C.S., Kim S. Construction of retroviral vectors with improved safety, gene expression, and versatility. J. Virol. 72:1998;994-1004
20. King J.A., Bridger J.M., Gounari F., Lichter P., Schulz T.F., Schirrmacher V., Khazaie K. The extended packaging sequence of MoMLV contains a constitutive mRNA nuclear export function. FEBS Lett. 434:1998;367-371
21. Kohn D.B., Sadelain M., Glorioso J.C. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat. Rev. Cancer. 3:2003;477-488
22. Krall W.J., Skelton D.C., Yu X.J., Riviere I., Lehn P., Mulligan R.C., Kohn D.B. Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells. Gene Ther. 3:1996;37-48
23. Labrador M., Corces V.G. Setting the boundaries of chromatin domains and nuclear organization. Cell. 111:2002;151-154
24. Lander M.R., Chattopadhyay S.K. A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ectropic, amphotropic, xenotropic, and mink cell focus-forming viruses. J. Virol. 52:1984;695-698
25. Lee K.H., Song S.U., Hwang T.S., Yi Y., Oh I.S., Lee J.Y., Choi K.B., Choi M.S., Kim S.J. Regeneration of hyaline cartilage by cell-mediated gene therapy using transforming growth factor beta 1-producing fibroblasts. Hum. Gene Ther. 12:2001;1805-1813
26. Metcalf J.P., Monick M.M., Stinski M.F., Hunninghake G.W. Adenovirus E1A 13S gene product up-regulates the cytomegalovirus major immediate early promoter. Am. J. Respir. Cell Mol. Biol. 10:1994;448-452
27. Miller A.D. Retrovirus packaging cells. Hum. Gene Ther. 1:1990;5-14
28. Miller, A.D., Rosman, G.J., 1989. Improved retroviral vectors for gene transfer and expression Biotechniques 7, 980-982, 984-986, 989-990.
29. Mougel M., Tounekti N., Darlix J.L., Paoletti J., Ehresmann B., Ehresmann C. Conformational analysis of the 5′ leader and the gag initiation site of Mo-MuLV RNA and allosteric transitions induced by dimerization. Nucleic Acids Res. 21:1993;4677-4684
30. Naviaux R.K., Costanzi E., Haas M., Verma I.M. The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J. Virol. 70:1996;5701-5705
31. Palu G., Parolin C., Takeuchi Y., Pizzato M. Progress with retroviral gene vectors. Rev. Med. Virol. 10:2000;185-202
32. Pfeifer A., Verma I.M. Gene therapy: promises and problems. Annu. Rev. Genomics Hum. Genet. 2:2001;177-211
33. Rigg R.J., Chen J., Dando J.S., Forestell S.P., Plavec I., Bohnlein E. A novel human amphotropic packaging cell line: high titer* complement resistance, and improved safety. Virology. 218:1996;290-295
34. Robbins P.D., Tahara H., Ghivizzani S.C. Viral vectors for gene therapy. Trends Biotechnol. 16:1998;35-40
35. Sandmeyer S. Integration by design. Proc. Natl. Acad. Sci. U.S.A. 100:2003;5586-5588
36. Schroder A.R., Shinn P., Chen H., Berry C., Ecker J.R., Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 110:2002;521-529
37. Trono D. Virology. Picking the right spot. Science. 300:2003;1670-1671
38. Wu X., Li Y., Crise B., Burgess S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science. 300:2003;1749-1751
39. Yu S.S., Kim J.M., Kim S. High efficiency retroviral vectors that contain no viral coding sequences. Gene Ther. 7:2000;797-804